WORKING WITH US

Challenging. Meaningful. Life-changing. Those aren’t words that are usually associated with a job. But working at Bristol Myers Squibb is anything but usual. Here, uniquely interesting work happens every day, in every department. From optimizing a production line to the latest breakthroughs in cell therapy, this is work that transforms the lives of patients, and the careers of those who do it. You’ll get the chance to grow and thrive through opportunities uncommon in scale and scope, alongside high-achieving teams. Take your career farther than you thought possible.
Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives. Read more: careers.bms.com/working-with-us .

POSITION SUMMARY

This Senior Director, Immunology & Neuroscience (I&N), Medical Evidence Generation (MEG) role in Global Medical Affairs manages the evidence generation for the I&N portfolio (including Medical Affairs Sponsored studies [MAST], Clinical Research Collaborations [CRC], and investigator-sponsored studies [ISR]) and provides leadership for the cross-functional teams executing on the book of work. In this role, he/she will have a key role in ensuring the strategic data generation needs for the I&N organization are executed with speed and rigor. The I&N Senior Director will lead and participate in cross-functional matrix leadership teams focused on building these relationships and actively sourcing research concepts that address critical evidence gaps for early and late assets being developed in prioritized indications. The Senior Director reports to the Immunology & Neuroscience Executive Director. Responsibilities include:

• Build, manage, and coach for sustained high performance an externally focused global team accountable for defining and executing the I&N portfolio to address key data gaps
• Coach a team of MEG Leads, inclusive of Clinical Scientists and Clinical Trial Physicians, in successful oversight of Medical clinical trials end-to-end (i.e., start-up, influence governance outcomes, partner with contract Manager/Lead for agreement initiation, negotiation, and execution, oversight throughout study and support readout)
• Design and drive strategies to successfully identify and advance new medical trials that accelerate the development of the BMS pipeline
• Should have experience in clinical concept development and partnering across the drug development continuum
• Project leadership, managing cross functional team members focused on scientific aspects (including results) and other study-related activities as appropriate
• Contribute to the evolution of the MEG organizational model and operational infrastructure
• Accountable for the I&N MEG book of work (including but not limited to MASTs, ISRs, CRCs, and IEP development) ensuring they are in alignment with the Integrated Evidence Plan (IEP), and executed with rigor and on time
• Provide accountability and oversight for the authoring and development of the medical study protocol and ICF, providing medical input during protocol development to ensure clinical relevance, scientific rigor, patient safety, and alignment with study objectives
• Accountable for ensuring scientific integrity and data quality is maintained during executions of medical trial, ensuring quality execution of deliverables for all phases (start-up/conduct/closure)
• Lead the team responsible for the co-development and maintenance of the IEPs, in partnership with Medical, HEOR, Development and other key internal stakeholders
• Partner closely with key stakeholders across Medical Affairs and Drug Development working on the I&N portfolio to ensure cohesiveness and one MEG voice
• Employ strong business acumen and fiscal stewardship focused on driving reciprocal scientific value creation and allocating resources consistent with company priorities
• Assist in reviews of concepts through RFP process, including providing context for ongoing book of work, area of interest development, and upcoming data read outs

Qualifications & Experience

• MD preferred (or x-US equivalent)
• 5+ years required clinical trial experience in pharmaceutical industry setting (e.g., Clinical Trial Physician, Clinical Scientist); expertise in drug development process and clinical research; with demonstrated proficiency in driving and managing company-sponsored clinical trials and leading teams
• 5+ years preferred strategic leadership experience in a pharmaceutical industry setting and possessing an in-depth understanding of clinical and business development, Medical Affairs, and Commercial functions related to the drug development process
• 10+ years of experience preferred in clinical science, clinical research, or equivalent
• Exhibits confidence and professional diplomacy, while effectively relating to people at all levels internally and externally
• Promotes a culture of scientific excellence, multidisciplinary problem solving, teamwork, consistency, flexibility, execution, quality, and effective communication
• Adeptness at building credibility with external investigators and collaborative partners competently balancing business and scientific acumen complemented by strong leadership behaviors, authenticity, agility, and an enterprise mindset
• Demonstrated ability to develop and sustain a high-performing team along with a proven ability to successfully lead teams (including matrix colleagues)
• Demonstrated track record of leadership in a complex, matrix environment
• Exceptional communication and interpersonal skills to influence decision-making at all levels of the organization
• This Position is preferably based at the Princeton Pike (PPK) site in Lawrenceville, NJ; Expected travel ~20%-30% globally.

• Build, manage, and coach for sustained high performance an externally focused global team accountable for defining and executing the I&N portfolio to address key data gaps
• Coach a team of MEG Leads, inclusive of Clinical Scientists and Clinical Trial Physicians, in successful oversight of Medical clinical trials end-to-end (i.e., start-up, influence governance outcomes, partner with contract Manager/Lead for agreement initiation, negotiation, and execution, oversight throughout study and support readout)
• Design and drive strategies to successfully identify and advance new medical trials that accelerate the development of the BMS pipeline
• Should have experience in clinical concept development and partnering across the drug development continuum
• Project leadership, managing cross functional team members focused on scientific aspects (including results) and other study-related activities as appropriate
• Contribute to the evolution of the MEG organizational model and operational infrastructure
• Accountable for the I&N MEG book of work (including but not limited to MASTs, ISRs, CRCs, and IEP development) ensuring they are in alignment with the Integrated Evidence Plan (IEP), and executed with rigor and on time
• Provide accountability and oversight for the authoring and development of the medical study protocol and ICF, providing medical input during protocol development to ensure clinical relevance, scientific rigor, patient safety, and alignment with study objectives
• Accountable for ensuring scientific integrity and data quality is maintained during executions of medical trial, ensuring quality execution of deliverables for all phases (start-up/conduct/closure)
• Lead the team responsible for the co-development and maintenance of the IEPs, in partnership with Medical, HEOR, Development and other key internal stakeholders
• Partner closely with key stakeholders across Medical Affairs and Drug Development working on the I&N portfolio to ensure cohesiveness and one MEG voice
• Employ strong business acumen and fiscal stewardship focused on driving reciprocal scientific value creation and allocating resources consistent with company priorities
• Assist in reviews of concepts through RFP process, including providing context for ongoing book of work, area of interest development, and upcoming data read out